Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

NCT01111903 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT01111903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01111903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2014
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer recurrent